4.7 Review

miR-490: A potential biomarker and therapeutic target in cancer and other diseases

Journal

JOURNAL OF CELLULAR PHYSIOLOGY
Volume 236, Issue 5, Pages 3178-3193

Publisher

WILEY
DOI: 10.1002/jcp.30119

Keywords

cancer; diagnosis; disease; microRNA; miR‐ 490; prognosis; therapy

Funding

  1. IIT Delhi
  2. Ministry of Human Resource and Development (MHRD)

Ask authors/readers for more resources

miR-490, a well-studied miRNA, is associated with the pathogenesis of various diseases, particularly showing potential in cancer diagnosis and prognosis. Multiple epigenetic and posttranscriptional mechanisms tightly regulate the levels of miR-490, with its targets involving cancer-related genes that impact various cancer hallmarks.
MicroRNAs (miRNAs) are small non-coding RNAs that function as posttranscriptional gene regulators. Among a pool of >2600 known human mature miRNAs, only a small subset have been functionally interrogated and a further smaller pool shown to be associated with the pathogenesis of a variety of diseases suggesting their critical role in maintaining homeostasis. Here, we draw your attention to one such miRNA, miR-490, that has been reported to be deregulated in a myriad of diseases (23 diseases) ranging from cardiomyopathy, depression, and developmental disorders to many cancer types (28 cancer types), such as hepatocellular carcinoma, gastric cancer, cancers of the reproductive and central nervous system among others. The prognostic and diagnostic potential of miR-490 has been reported in many diseases including cancer underlining its clinical relevance. We also collate a complex plethora of epigenetic (histone and DNA methylation), transcriptional (TF), and posttranscriptional (lncRNA and circRNA) mechanisms that have been shown to tightly regulate miR-490 levels. The targets of miR-490 involve a range of cancer-related genes involved in the regulation of various cancer hallmarks like cell proliferation, migration, and invasion, apoptotic cell death, angiogenesis, and so forth. Overall, our in-depth review highlights for the first time the emerging role of miR-490 in disease pathology, diagnosis, and prognosis that assigns a unique therapeutic potential to miR-490 in the era of precision medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment

Rahul Agrawal, Ankita Garg, Prit Benny Malgulwar, Vikas Sharma, Chitra Sarkar, Ritu Kulshreshtha

INTERNATIONAL JOURNAL OF CANCER (2018)

Article Cell Biology

HIF1α and p53 Regulated MED30, a Mediator Complex Subunit, is Involved in Regulation of Glioblastoma Pathogenesis and Temozolomide Resistance

Anubha Shukla, Srishti Srivastava, Jayant Darokar, Ritu Kulshreshtha

Summary: The study found that MED30 is overexpressed in GBM tissues and cell lines, induced by factors in the tumor microenvironment, and positively correlated with p53 and HIF1 alpha levels in GBM tissues. MED30 promotes cell proliferation and reduces migration capabilities in GBM cell lines, and also confers sensitivity to temozolomide and modulates p53 levels in vitro. Overall, the results suggest that MED30 may play a role in GBM pathogenesis and could be a potential diagnostic and therapeutic target, urging further exploration of its interactome and target networks.

CELLULAR AND MOLECULAR NEUROBIOLOGY (2021)

Article Biochemistry & Molecular Biology

miR-490 suppresses telomere maintenance program and associated hallmarks in glioblastoma

Omkar Suhas Vinchure, Kurt Whittemore, Deependra Kushwah, Maria A. Blasco, Ritu Kulshreshtha

Summary: miR-490 targets multiple genes to regulate telomere maintenance in GBM, exerting tumor suppressive effects, impacting stemness and senescence, activating DNA damage response, and potentially holding therapeutic significance in GBM treatment.

CELLULAR AND MOLECULAR LIFE SCIENCES (2021)

Article Oncology

Hypoxia-inducible miR-196a modulates glioblastoma cell proliferation and migration through complex regulation of NRAS

Sonam Takkar, Vikas Sharma, Sourabh Ghosh, Ashish Suri, Chitra Sarkar, Ritu Kulshreshtha

Summary: This study identified miR-196a as a hypoxia-inducible and hypoxia-inducible factor (HIF)-regulated miRNA that plays an oncogenic role in GBM. It was significantly up-regulated in TCGA-GBM, CGGA glioma and Indian GBM patient cohorts. miR-196a overexpression promoted cellular proliferation, migration, spheroid and colony formation, and inhibited apoptosis, while inhibition of miR-196a yielded opposite results, suggesting an oncogenic role.

CELLULAR ONCOLOGY (2021)

Review Cell Biology

Metastasis associated long noncoding RNAs in glioblastoma: Biomarkers and therapeutic targets

Garima Yadav, Ritu Kulshreshtha

Summary: Recent studies have highlighted the significance of long noncoding RNAs (lncRNAs) in GBM metastasis, showing potential as diagnostic/prognostic biomarkers and therapeutic targets. The intricate network of lncRNA/miRNA/protein plays a crucial role in regulating metastasis-associated genes, offering insights into potential therapeutic strategies for GBM treatment.

JOURNAL OF CELLULAR PHYSIOLOGY (2022)

Article Biochemistry & Molecular Biology

MED12 is overexpressed in glioblastoma patients and serves as an oncogene by targeting the VDR/BCL6/p53 axis

Srishti Srivastava, Hima Makala, Vikas Sharma, Vaishali Suri, Chitra Sarkar, Ritu Kulshreshtha

Summary: This study reveals the overexpression of a subunit of the mediator complex, MED12, in glioblastoma and shows its role in promoting tumor cell proliferation, migration, and inhibiting apoptosis. The study also identifies MED12 as an important mediator of the VDR signaling pathway and highlights its potential as a therapeutic target for glioblastoma.

CELLULAR AND MOLECULAR LIFE SCIENCES (2022)

Article Materials Science, Biomaterials

Transglutaminase-Polyethyleneimine Nanoflowers Mediated Cellular Delivery of Anti-miR-210 for Effective Glioblastoma Therapy

Indranil Mondal, Syeda Warisul Fatima, Swati Priya, Sagar Sengupta, Sunil Kumar Khare, Ritu Kulshreshtha

Summary: A novel nanostructure called TGNFs has been developed for efficient delivery of anti-miR-210 to glioblastoma cells, resulting in decreased proliferation and migration and increased apoptosis. This method shows potential as a delivery agent in miRNA inhibition therapy.

ACS BIOMATERIALS SCIENCE & ENGINEERING (2023)

Review Cell Biology

Insights into the regulatory role and clinical relevance of mediator subunit, MED12, in human diseases

Srishti Srivastava, Ritu Kulshreshtha

Summary: Transcriptional dysregulation is central to many diseases, with MED12 playing a critical role as a master regulator of the mediator complex involved in transcription. Mutations or differential expression of MED12 are associated with various human disorders and cancers, making it an attractive novel therapeutic target.

JOURNAL OF CELLULAR PHYSIOLOGY (2021)

Article Chemistry, Inorganic & Nuclear

Development of novel ruthenium(II)-arene complexes displaying potent anticancer effects in glioblastoma cells

Priyaranjan Kumar, Indranil Mondal, Ritu Kulshreshtha, Ashis K. Patra

DALTON TRANSACTIONS (2020)

No Data Available